Advertisements

Symbicord

Quick links to important sections

Symbicord

Advertisements
Advertisements

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Symbicord

Symbicord is a prescription-only medicine specifically formulated as a fixed-dose combination (FDC) product, uniting two different active agents into a single inhaler for administration via the pulmonary route. The medicine's structure ensures that both essential components for chronic airway management are delivered simultaneously.

Property Description
Active ingredients Budesonide and Formoterol Fumarate
Form Dry powder for inhalation or suspension for inhalation
Pharmacological class ICS/LABA combination (Inhaled Corticosteroid and Long-acting β₂-agonist)
Origin Synthetic
General purpose Controller medication for chronic airway management

Dual Classification: A Fixed-Dose Combination

Symbicord is primarily classified as an Inhaled Corticosteroid and Long-acting β₂-agonist combination (ICS/LABA), placing it in the category of controller medications used for maintenance treatment of chronic airway diseases. The combination's primary action is designed for regular daily use to control the persistent underlying symptoms of obstructive airway disorders. Clinically recognized for its vital role in long-term disease management, this FDC structure differentiates Symbicord's positioning compared to single-agent inhalers, offering therapeutic efficiency for adults and adolescents in one device.

Composition and General Purpose

The product’s efficacy is based on the synergy between its two synthetic active ingredients. Budesonide is the Inhaled Corticosteroid (ICS) component, which provides necessary anti-inflammatory action in the airways, while Formoterol Fumarate is the Long-acting β₂-agonist (LABA) component, which induces long-lasting bronchodilation. Combining these agents is a widely accepted strategy in long-term respiratory care, offering complementary therapeutic effects. The general purpose is prophylaxis and the support of long-term respiratory function as a controller medication, stabilizing the patient's breathing rather than acting as a rapid reliever.

Regulatory References

  1. NIH
  2. NIH Drug Information
Advertisements

What side effects are possible with Symbicord?

Possible Side Effects and Safety Information

The safety profile of Symbicort (budesonide/formoterol) is documented by governmental regulatory agencies, categorizing potential adverse reactions by frequency and affected body system. This information is strictly descriptive and non-advisory.


Frequency-Classified Adverse Reactions

Adverse events are formally classified based on incidence in clinical data:

  • Very Common: Headache (in some populations).
  • Common: Oral candidiasis (thrush), Palpitations, Tremor, Throat irritation, mild bronchodilator-induced symptoms.
  • Uncommon: Tachycardia, Muscle cramps, Anxiety, Sleep disturbances, Agitation.
  • Rare: Anaphylactic reactions, Hypokalaemia (low potassium), Cardiac arrhythmias.
  • Very Rare: Signs of systemic glucocorticosteroid effects (e.g., adrenal suppression, cataract/glaucoma).

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight rare but clinically significant adverse reactions and important safety limitations:

  • Serious Adverse Reactions: These include paradoxical bronchospasm (acute worsening of breathing immediately after use) and severe hypersensitivity reactions (e.g., anaphylaxis). These require immediate medical attention.
  • Systemic Effects: Long-term, high-dose use of inhaled corticosteroids requires monitoring due to the potential for systemic effects, such as a decrease in bone mineral density or adrenal suppression.
  • Time-Related Patterns: Effects like tremor and palpitations are often transient and typically lessen after a few days of continuous use.

Population-Specific Safety Notes

  • Hepatic Impairment: Clearance of budesonide may be reduced in patients with severe liver impairment, necessitating close monitoring for systemic corticosteroid exposure.
  • Pregnancy/Lactation: Use is warranted only if the potential benefit outweighs the potential risk. Specific data are referenced in regulatory texts.
Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for an overdose of Symbicord, which combines budesonide and formoterol, is structured around the systemic effects of its two components. The primary acute effects are related to Formoterol, the long-acting beta2-agonist.

Documented Overdose Manifestations

Overdose presentations documented in regulatory labeling are often associated with excessive beta-adrenergic stimulation. These symptoms include tremor, palpitations, tachycardia (rapid heartbeat), and headache. Metabolic complications such as hyperglycemia (high blood sugar) and hypokalemia (low potassium in the blood) are also documented effects that require clinical monitoring.

Following prolonged or very high doses of the budesonide component, systemic corticosteroid effects, including hypercorticism and adrenal suppression, may occur.

Required Emergency Actions

The official guidance mandates that patients who find the treatment ineffective or who exceed the highest recommended dose must seek medical attention. Urgent medical assessment is also required for sudden and progressive deterioration in the control of the underlying respiratory condition. In cases of suspected overdose, the prescribed response involves symptomatic and supportive treatment. Clinical monitoring is mandated, specifically to assess for the metabolic risks of hypokalemia and hyperglycemia.

Regulatory documents emphasize that no specific antidote is known. The risk of dose-related effects is noted to potentially increase in patients with severe hepatic impairment due to altered drug exposure.

Advertisements

Therapeutic Uses of Symbicord

Quick Facts

  • Primary Therapeutic Domains: Asthma and Chronic Obstructive Pulmonary Disease (COPD).
  • Key Action: Supports long-term maintenance treatment of these chronic respiratory conditions.
  • Goal of Use: Aims to improve airflow and assist in the management of exacerbations.

Symbicord is authorized for the long-term, daily management of two primary respiratory conditions: asthma and Chronic Obstructive Pulmonary Disease (COPD).

For asthma, the medication provides maintenance treatment in patients whose symptoms are not adequately addressed by other standard long-term control medicines, such as an inhaled corticosteroid alone. It is intended for individuals whose condition warrants the administration of an inhaled corticosteroid alongside a long-acting bronchodilator. This therapy aims to help sustain better breathing and support the reduction of symptoms over time.

In the context of COPD, including chronic bronchitis and emphysema, Symbicord is designated for the maintenance treatment of airflow obstruction. It is also utilized to help reduce the frequency of disease exacerbations, which are periods of worsening symptoms. It is critical to note that this therapy is not intended for the relief of sudden, acute breathing difficulty.

Regulatory References

  1. NIH MedlinePlus guidance
Advertisements

Eligibility and Restrictions for Use

Symbicord (budesonide/formoterol) is a combination inhaler generally used for the maintenance treatment of asthma in patients aged 12 years and older, and for the maintenance treatment of airflow obstruction in adults with Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and emphysema. It is typically prescribed only when asthma is not adequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid alone.


When Symbicord Should Not Be Used

Symbicord is not indicated for the relief of acute bronchospasm or to treat an asthma attack or sudden worsening of COPD. A rapid-acting rescue inhaler is needed for these situations.

Contraindications for use include known hypersensitivity or allergic reaction to budesonide, formoterol, or any other ingredients in the product.


Use with Caution

Tell your healthcare provider about all existing medical conditions, as caution is advised in patients with:

  • Cardiovascular issues (e.g., heart rhythm disorders, high blood pressure)
  • Seizure disorders
  • Diabetes
  • Thyroid problems (specifically hyperthyroidism)
  • Untreated infections (e.g., tuberculosis, fungal, viral, or bacterial)
  • Osteoporosis
  • Eye problems (e.g., glaucoma or cataracts)
  • Severe liver impairment

Additionally, Symbicord is not recommended for routine use in children under 6 years of age. Decisions regarding its use during pregnancy or breastfeeding require careful consideration of the potential benefits versus the risks.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with Symbicord (budesonide/formoterol) are primarily categorized by their effect on drug metabolism (pharmacokinetic) or their combined physiological effects (pharmacodynamic), according to regulatory documentation.

Pharmacokinetic Interactions

Interacting Agents Effect on Symbicord Implication
Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir) Increased systemic exposure of budesonide (corticosteroid component). Increased risk of systemic corticosteroid effects, such as adrenal suppression.
Grapefruit Juice Increased systemic exposure of budesonide. Avoid consumption during treatment due to potential for increased exposure.

Pharmacodynamic Interactions

Interacting Agents Key Interaction/Risk
Other Long-Acting beta2-Agonists (LABAs) Risk of overdose due to additive formoterol exposure; co-administration is not recommended.
Non-selective beta-Blockers May block the bronchodilator effect of formoterol and cause severe bronchospasm.
Diuretics (Non-potassium-sparing) Potential to worsen formoterol-associated hypokalemia (low potassium) and/or ECG changes.
MAOIs or TCAs (Antidepressants) May potentiate formoterol’s effect on the cardiovascular system, requiring caution.

Population-Specific Interaction Notes

Patients with severe hepatic impairment may experience increased systemic exposure to both budesonide and formoterol because both components are primarily cleared by the liver.

Advertisements

Mechanism of Action

How Symbicord Works: Mechanism of Action

The action of Symbicord is defined by the complementary pharmacodynamic mechanisms of Budesonide and Formoterol Fumarate. Budesonide acts as an agonist at the intracellular Glucocorticoid Receptor (GR). The activated Budesonide-GR complex engages in nuclear transrepression of pro-inflammatory factors, such as NF-kappa B, fundamentally suppressing the gene expression of inflammatory mediators. This mechanism initiates a long-term physiological outcome involving reduced airway mucosal edema and cellular infiltration.

Formoterol is a full agonist at the cell-surface beta2-Adrenoceptor (beta2-AR) on bronchial smooth muscle cells. Activation triggers the cAMP cascade, which inactivates the enzyme responsible for muscle contraction. The resulting physiological effect is the rapid relaxation of the bronchial smooth muscle, decreasing airflow resistance within 1-3 minutes of use. Mechanistic synergy occurs because Budesonide's action increases the expression and sensitivity of the beta2-ARs, reinforcing Formoterol's bronchodilator mechanism and contributing to the sustained physiological modulation of the airways.

Advertisements

Dosage and Administration Information

Instruction Map: How to use Symbicord — Official Administration Guidelines

This information details the administration guidelines for Symbicort (budesonide/formoterol fumarate dihydrate) established for the proper use of the medication.


Administration Scope

Feature Guideline Description
Route of administration Oral inhalation only.
Dosing schedule (maintenance) Two inhalations of the prescribed strength twice daily, every day.
Timing in relation to meals Administer in the morning and evening, approximately 12 hours apart. Timing is not dependent on meals.
Preparation requirements A new inhaler must be primed by shaking well for 5 seconds and releasing two test sprays. Re-priming is required if the inhaler is unused for more than 7 days or has been dropped.
Age-group administration rules Children 6 to < 12 years are prescribed the 80/4.5 mcg strength, 2 inhalations twice daily. Adults and adolescents (ge 12 years) use higher strengths as determined by the prescriber.
Missed-dose rules If a dose is missed, the next dose should be taken at the regular scheduled time. Do not take extra inhalations to compensate.
Special procedural conditions The patient must rinse the mouth with water and spit out (do not swallow) immediately after each dose.

Resulting Procedural Structure

The required sequence for proper administration involves:

  • Priming the device if necessary, followed by shaking the inhaler well for 5 seconds before each inhalation.
  • Taking a slow, deep breath while pressing the canister to actuate the dose.
  • Holding the breath for approximately 10 seconds or as long as comfortable.
  • Repeating the inhalation procedure for the second prescribed puff.
  • Completing the process by rinsing the mouth with water and spitting to minimize local drug residue.

This structured protocol defines the continuous, twice-daily use of Symbicort as a maintenance therapy. The instructions strictly outline the mechanical operation, precise timing, and required post-inhalation action to ensure the medication is used exactly as intended.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Symbicord


Evidence for Use in Managing Asthma Symptoms

This section summarizes available clinical trial data evaluating how Symbicord was studied to understand how symptoms evolved in people with asthma needing regular symptom monitoring.

Research has examined its use in asthma, a condition characterized by fluctuating or episodic manifestations. These studies focused on outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. Findings describe patterns observed in the studies related to how patients reported their breathing and their ability to maintain regular daily activities. Data show patterns related to changes in lung function test results and a decrease in outcomes describing episodic or acute changes where symptoms become more noticeable. Study results reflect the specific conditions and populations under which they were conducted.


Evidence for Use in Managing Chronic Obstructive Pulmonary Disease (COPD)

This section outlines research studies investigating Symbicord as a subject of research to explore outcomes reflecting daily functioning or activity level and outcomes describing episodic or acute changes in people with Chronic Obstructive Pulmonary Disease (COPD).

Symbicord was studied for use in COPD, a condition marked by functional limitations and periods of heightened symptom activity. Studies explored whether its use was associated with outcomes capturing phases of heightened symptom activity and outcomes describing episodic or acute changes. The evidence suggests that in patients who participated, data show patterns related to changes in physiological measures. However, not all findings were consistent across all measured outcomes, and certainty remains low for certain aspects. Comparative evidence is lacking against all other available treatment options.


Long-term Studies and Follow-up

This section summarizes what has been observed regarding Symbicord over extended periods, including the durability of patterns observed and any available data on outcomes from long-term follow-up studies.

Research has explored what happens when people use Symbicord over extended periods, monitoring outcomes related to systemic or functional imbalance. The data for long-term use are still emerging, and there is limited information for long-term outcomes for many groups. Long-term effects are not fully established for all potential outcomes, and follow-up durations were limited in some of the available evidence. Research is ongoing to contribute to the body of evidence regarding use over many years.


Evidence in Specific Patient Groups

This section outlines what studies have evaluated the use of Symbicord in specific groups, such as children and older adults.

Studies in Children and Adolescents

Symbicord was evaluated in studies involving children and adolescents. Research focused on how the medication was observed in this younger population, looking at outcomes related to physical discomfort. Subgroup findings are uncertain for certain specific age ranges or severity levels.

Studies in Older Adults

Older adults was observed in clinical studies. Data show patterns related to changes in physiological measures. However, sample sizes were modest and evidence quality varies across studies, meaning data for certain groups remain insufficient.


What is Still Unclear About Symbicord

This section synthesizes the main evidence gaps, inconsistent findings, and areas where more research is needed.

Research provides context but not individual predictions, and the evidence highlights what is known—and what is still uncertain. Comparative evidence is lacking or inconsistent. For special populations, data for certain groups remain insufficient, and findings were mixed in some trials, meaning certainty remains low. The research does not determine whether an individual will respond similarly to the group patterns observed, and more research is needed to fill these knowledge gaps.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Symbicord (FAQ)


Q: How long does it usually take to feel the effects after starting Symbicord?

Symbicord is a combination of two medicines. The Formoterol component is a bronchodilator described as having a rapid onset, with the effect of relaxing the bronchial smooth muscle often observed within 1 to 3 minutes based on pharmacodynamic studies. However, the Budesonide component works as a controller medicine to reduce chronic airway inflammation. The full, sustained benefit from the anti-inflammatory action may take several weeks of continuous use to become fully noticeable, as noted in official product information.


Q: Does Symbicord cause weight gain?

Regulatory documents list weight gain as an uncommon side effect reported in some studied populations. Systemic effects from the inhaled corticosteroid component are a known consideration. Any unexpected or significant changes in body weight warrant discussion with the prescriber or a healthcare professional.


Q: Are there any common over-the-counter cold medicines that interact with Symbicord?

Interactions can occur between the Formoterol component (a beta2-agonist) and certain drugs found in common cold or decongestant products, particularly those in the sympathomimetic class (like pseudoephedrine). These interactions may potentially lead to increased side effects such as elevated heart rate or blood pressure. It is important to review all over-the-counter medication labels and disclose them to the prescribing professional.


Q: Can taking Symbicord cause voice changes or hoarseness?

Yes, regulatory and post-marketing safety data indicate that both hoarseness (laryngitis) and voice changes (dysphonia) have been reported as potential effects. Due to local drug deposition, the official administration guidelines include rinsing the mouth with water and spitting it out immediately after each dose.


Q: How long does one Symbicord inhaler typically last for a patient?

The pressurized metered-dose inhaler (pMDI) version of Symbicord usually contains 120 actuations (doses) when dispensed. Based on the standard maintenance schedule of two inhalations twice daily (four puffs per day), one inhaler is designed to last for approximately 30 days of continuous use.


Q: Is Symbicord the same as Symbicort, or are they different drugs?

The name used in most major regulatory documents for this drug is Symbicort (with a 't'), which refers to the combination of budesonide and formoterol fumarate dihydrate. While 'Symbicord' (with a 'd') is often used informally or may be a brand name in a specific region, official medical and regulatory information is nearly universally tied to the Symbicort spelling.


Q: Is Symbicord commonly used for conditions other than asthma and COPD?

According to the official Indications and Usage sections, Symbicord is only indicated and approved for the maintenance treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). Use for other lung or airway conditions is not included in the approved labeling.


Q: Are there specific vitamins or supplements that are known to interact with Symbicord?

Drug labels advise caution regarding substances that affect the liver's CYP3A4 enzyme, as this can increase the levels of the budesonide component in the body. Additionally, supplements that affect potassium levels or heart rhythm may interact with the formoterol component. It is important to disclose all herbal products, supplements, and vitamins to the prescribing professional.


Q: What does the word 'corticosteroid' mean in the context of Symbicord?

Symbicord contains the inhaled corticosteroid, Budesonide. A corticosteroid is a synthetic medicine that acts like natural hormones to reduce inflammation and swelling in the airways. It is the controller component that helps manage the underlying chronic condition, as described in official product information.


Q: Does Symbicord contain gluten or lactose?

The dry powder formulation of Symbicord (Turbuhaler) typically uses lactose as an inactive carrier substance to help deliver the medicine. While gluten is not typically listed as an ingredient, for patients with severe sensitivities, verification of the inactive excipient list for their specific product version with a pharmacist is recommended.


Q: What kind of specialist typically prescribes Symbicord?

Symbicord is classified as a prescription-only medicine. It is typically prescribed by a healthcare provider who manages chronic breathing conditions. This often includes a Primary Care Physician, a Pulmonologist, or an Allergist/Immunologist.


Q: Is there a generic version of Symbicord available in certain regions?

Yes, regulatory agencies like the FDA have approved generic versions of the budesonide/formoterol combination inhaler. Official information indicates the availability of such generic products, though it may vary based on your specific region, product strength, and ongoing market exclusivity.


Q: If I stop taking Symbicord, what kind of changes might happen to my condition?

Since Symbicord is approved as a maintenance medicine designed for daily, continuous treatment of chronic conditions, stopping its use will likely lead to a return or worsening of the underlying asthma or COPD symptoms. Regulatory guidelines state that maintenance medication should not be discontinued without consultation and guidance from a healthcare provider.


Q: Does Symbicord affect a person's ability to drive or operate machinery?

Official regulatory documents, such as the European Summary of Product Characteristics (SmPC), state that Symbicord is not expected to adversely affect a person's ability to drive or use heavy machinery. However, if you experience dizziness or tremor, caution is advised.


Q: What is the usual duration of action of one dose of Symbicord?

Symbicord contains Formoterol, which is a long-acting beta2-agonist (LABA). This classification means the bronchodilating effect is designed to provide sustained relief, lasting for approximately 12 hours after a single dose. This duration supports its use as a twice-daily maintenance treatment.

Advertisements

How should Symbicord be stored and disposed of?

Symbicord should be stored at controlled room temperature, typically between 68^circmathrmF and 77^circmathrmF (20^circmathrmC and 25^circmathrmC), with the mouthpiece cover firmly in place. It is important to keep the inhaler away from excessive heat, cold, moisture, and direct sunlight. For the pressurized inhaler (Symbicord HFA), the contents are under pressure; do not puncture the canister or store it near heat or open flame, as temperatures above 120^circmathrmF (49^circmathrmC) may cause it to burst.

After removing a new inhaler from its protective foil pouch, it must be used within three months, regardless of the number of doses remaining. You must stop using the inhaler when the dose counter reaches zero.

Do not dispose of Symbicord or other old or unwanted medicines via household waste or wastewater. For safe disposal, return the inhaler to a pharmacy as part of an established drug take-back or return program. The canister inside the pressurized inhaler contains propellants that should be disposed of in an environmentally safe way.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Symbicord found in:

A-Z Index: